Published • loading... • Updated
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring A 139.85% Potential Upside In The Biotechnology Sector
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring A 139.85% Potential Upside In The Biotechnology Sector
Investors with an eye on the biotechnology sector might want to pay attention to REGENXBIO Inc. (NASDAQ: RGNX), a clinical-stage company specializing in gene therapies. With a market capitalization of approximately $647.88 million, REGENXBIO stands as a significant player in the healthcare industry, leveraging its proprietary NAV Technology Platform to address genetic disorders. The company’s stock is currently priced at $10.12, showing a modest…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
